Spondyloarthritis & psoriatic arthritis
Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network
Authors' conclusion
The results of this real-world study of Canadian patients with axSpA, one of the first of its kind, support the effectiveness of SEC for treatment of axSpA.
Study context
- Population
- Canadian patients with axial spondyloarthritis (axSpA) aged 18 to 65 years within the Canadian Spondyloarthritis (CanSpA) Research Network treated with secukinumab
- Participants
- 146 patients
- Outcome
- Retention and clinical effectiveness (proportion in remission and change in disease activity using multiple clinical indices)
- Follow-up
- 12 months postindex
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
12 months
Overall retention
62.9%
Low disease activity (BASDAI < 4)
29.2%
Remission based on ASDAS
2%
Bath Ankylosing Spondylitis Metrology Index scores improved from baseline to 12 months by more than
60%
Observational data: associations, not effects.
Original publication
Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network. J Rheumatol. Published 15 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →